Telangana DCA Makes 277 Seizures Since January

Hyderabad: Telangana accounts for over 35% of India’s pharmaceutical production, with Hyderabad earning the moniker ‘Bulk Drug Capital of India’.

The State has seen substantial growth in the pharmaceutical sector over the past few years. This growth, however, has also brought challenges, including a rise in the production and sale of spurious, unauthorised and counterfeit drugs.

Between January and July 2024, the Telangana Drugs Control Administration (DCA) conducted 12,575 inspections; this led to 277 seizures for various violations, 1,963 instances of departmental action, and 51 convictions.

The seizures, included six cases of spurious drugs; 61 cases of overpricing; 98 cases under the Drug and Magic Remedies (Objectionable Advertisements) Act, 1954; 34 cases involving unlicensed medical shops and warehouses; 14 cases of medicines marketed as food products; three cases of unlicensed cosmetics manufacturing; and two cases of production and sale of banned drugs.

According to the DCA, the State has 702 drug manufacturing units, 53 approved drug testing labs, 273 blood centres and 43,023 medical shops.

Some of the major seizure incidents by the DCA include a search in March at Kodad in Suryapet, where a person was found operating an unlicensed medical shop, leading to a seizure of stock worth ₹12.3 lakh. In April, unauthorised drug manufacturing was uncovered at Ovoid Pharmachem in Jeedimetla, Medchal Malkajgiri, leading to seizure of stocks worth ₹23.9 lakh.

Additionally, the DCA targeted clinics run by quacks (unqualified medical practitioners), conducting 59 searches and seizing medicines worth ₹33.16 lakh over the seven-month period.

Related Posts

  • Pharma
  • February 5, 2025
  • 119 views
Pharma stock jumps after it launches Kojiglo serum in India for facial hyperpigmentation

A leading pharmaceutical powerhouse renowned for innovative skincare solutions has unveiled its latest breakthrough in tackling facial hyperpigmentation. The groundbreaking serum, featuring a first-of-its-kind dual liposomal technology in India, promises…

  • Pharma
  • February 5, 2025
  • 127 views
Uniform Code Of Pharmaceuticals Marketing Practices 2024 Outlines Guidelines Regarding Promotion Of Drugs Among Doctors: Minister

New Delhi: With the aim of preventing unethical marketing and ensuring responsible promotion of pharmaceutical products by regulating interactions between doctors / registered medical practitioners (RMPs) and representatives of pharmaceutical…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

As Always Ahead of Game in healthcare, Doc was first to vote too

As Always Ahead of Game in healthcare, Doc was first to vote too

Pharma stock jumps after it launches Kojiglo serum in India for facial hyperpigmentation

Pharma stock jumps after it launches Kojiglo serum in India for facial hyperpigmentation

Uniform Code Of Pharmaceuticals Marketing Practices 2024 Outlines Guidelines Regarding Promotion Of Drugs Among Doctors: Minister

Uniform Code Of Pharmaceuticals Marketing Practices 2024 Outlines Guidelines Regarding Promotion Of Drugs Among Doctors: Minister

Dabur reduces strategic review cycle to 3 years amidst short-term volatility, FMCG slowdown

Dabur reduces strategic review cycle to 3 years amidst short-term volatility, FMCG slowdown

Sun Pharma appoints Aalok Shanghvi as Chief Operating Officer

Sun Pharma appoints Aalok Shanghvi as Chief Operating Officer

Alembic Pharma Q3 results: PAT falls 23.29% amid market headwinds

Alembic Pharma Q3 results: PAT falls 23.29% amid market headwinds